Lexicon Pharmaceuticals, Inc. (LXRX), a biopharmaceutical company announced new data from its recently completed Phase 2 study of its investigational drug telotristat etiprate for carcinoid tumors. Through the trial, the drug achieved its primary endpoint that is the reduction of bowel movements from baseline at week 12 in 46.4 percent of the patients involved in the study and suffering from metastatic carcinoid syndrome. In addition, the company said it would present the data from the trial at the North American Neuroendocrine Tumor Society on October 13 in California.
Further, the company added Telotristat etiprate, administered orally was well tolerated by the patients with only three of the patients reporting serious adverse events, none of which was related to study drug.
In a statement, the company said it is also initiating a 12-week registrational Phase 3 trail that is designed to test the drug's safety, efficacy after its positive outlook in the Phase 2 trials, said Lexicon in a statement.
For comments and feedback contact: editorial@rttnews.com
Business News
August 21, 2026 14:42 ET The minutes of the latest policy meeting of the Federal Reserve, housing market data and manufacturing sector survey results were the main news for the U.S. economy this week. In Europe, inflation data from the U.K. was the highlight, while consumer price data from Japan drew attention in Asia.